Learn More
BACKGROUND The FOLFOXIRI regimen developed by the Gruppo Oncologico Nord Ovest (GONO) demonstrated higher activity and efficacy compared with FOLFIRI in metastatic colorectal cancer (mCRC). Panitumumab is effective in some patients with KRAS codon 12-13 wild-type mCRC. KRAS codon 61, HRAS, NRAS, and BRAF V600E mutations might predict resistance to(More)
BACKGROUND The role of second-line chemotherapy (CT) is not established in advanced biliary tract cancer (aBTC). We investigated the outcome of aBTC patients treated with second-line CT and devised a prognostic model. METHODS Baseline clinical and laboratory data of 300 consecutive aBTC patients were collected and association with overall survival (OS)(More)
Major hepatectomy (MH) is often considered the only possible approach for colorectal liver metastasis (CRLM) at the hepato-caval confluence (CC), but it is associated with high morbidity and mortality. With the aim to reduce MH, we developed the "minor-but-complex" (MbC) technique, which consists in the resection of less than 3 adjacent liver segments with(More)
We have read with great interest the recent paper by Lamarca et al. [1], in which the authors conducted a systematic review of the literature to evaluate the level of evidence behind the use of second-line chemotherapy for patients with advanced biliary tract cancer (aBTC). The authors collected data of 761 patients from 14 phase II trials and 9(More)
The enhancer of zeste-homolog 2 (EZH2) is involved in cancer development through gene silencing by trimethylation of lysine 27 of histone 3 (H3K27me3). The C/C genotype for the EZH2 rs3757441 single-nucleotide polymorphism (SNP) is linked with poor prognosis in metastatic colorectal cancer (CRC), but molecular and pathological characterization of this SNP(More)
Sir, We have read with great interest the recent paper by Portal et al (2015), who reported the results of a prospective multicentre cohort study evaluating the efficacy and safety of nab-paclitaxel plus gemcitabine after FOLFIRINOX failure in patients with metastatic pancreatic cancer (mPC). The authors collected the data of 110 patients from 12 French(More)
  • 1